DIRS.INFO The most relevant business & tech news

☆ 'Mag 7' leads reversal — plus, we're adding a new stock to our Bullpen watchlist
▼ + stars: | 2024-11-19 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Next, we are going outside our current holdings and adding drugmaker Bristol Myers Squibb to the Bullpen, our watchlist of stocks that could join the portfolio. New Jersey-based Bristol Myers is in the midst of a transition phase under the leadership of new CEO Chris Boerner. Companies reporting earnings before the open Wednesday include Club stock TJX Companies , along with Target , Williams-Sonoma , and ZIM Integrated . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Robert F, Kennedy Jr, Kennedy, Donald Trump, Wall, Eli Lilly, Bristol Myers, Chris Boerner, Boerner, Karuna, we'll, Stanley Black, Decker, Jim Cramer's, Jim Organizations: CNBC, ., Club, Nvidia, Dow Jones, of Health, Human Services, Senate, Bristol Myers Squibb, Bristol, pharma, Karuna Therapeutics, FDA, JPMorgan, Keysight Technologies, TJX Companies, Target, Williams, ZIM, Jim Cramer's Charitable Locations: New Jersey, U.S, Sonoma

☆ Bristol Myers suddenly has a big lead in schizophrenia treatment, says Jim Cramer
▼ + stars: | 2024-11-18 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Bristol Myers suddenly has a big lead in schizophrenia treatment, says Jim Cramer'Mad Money' host Jim Cramer looks at recent stock movement in pharmaceuticals.

Persons: Bristol Myers, Jim Cramer

☆ Here's why Jim Cramer is hesitant to buy this AI chip stock right now
▼ + stars: | 2024-11-12 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. If management has anything positive to say about the highly profitable segment, it "would really move the stock," Jim said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, we've, Jim, Evercore, Stocks, Bristol Myers, Shopify, Tyson, Okta, Jim Cramer's Organizations: CNBC, Club, Home Depot, Citigroup, Analysts, Broadcom, Google, Nvidia, Disney, Evercore ISI, Netflix

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Tesla, Meta, Snowflake, Walmart, Wells Fargo, Alphabet & more
▼ + stars: | 2024-11-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

Here are Tuesday's biggest calls on Wall Street: Loop initiates NXP Semiconductor as buy The firm said it's bullish on the semiconductor company. Morgan Stanley reiterates Walmart as overweight Morgan Stanley raised its price target on the stock to $89 per share from $82 ahead of earnings next week. Morgan Stanley reiterates Tesla as overweight Morgan Stanley said it's sticking with the stock heading into a Trump administration. Morgan Stanley upgrades International Flavors to overweight from equal weight Morgan Stanley said in its upgrade of International Flavors that the fragrance and spice company is undervalued. Morgan Stanley upgrades Viking to overweight from equal weight Morgan Stanley said it sees an attractive entry point for the cruise company.

Persons: it's bullish, NXPI, Mizuho, it's, Morgan Stanley, WMT, Tesla, VIK, Redburn, Ross, Robinson, Wells, Bristol Myers, MoffettNathanson, D.A, Davidson, Snowflake Organizations: Semiconductor, NXP Semiconductor, Nvidia, Mizuho, TAM, 4Q, Citi, Deutsche Bank, Deutsche, " Bank of America, & Co, Bank of America, Apple Locations: eCommerce, VIK, OW, Wells Fargo, Bristol

☆ Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
▼ + stars: | 2024-10-31 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street's expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term growth. Bristol Myers previously said it expected sales to rise in the "upper end" of the low single-digit range. The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and funnel that money into key drug brands and research and development programs. Notably, the Food and Drug Administration approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy during the quarter.

Persons: Bristol Myers, Joe Biden's, Bristol Myers Squibb's Organizations: Bristol Myers Squibb, LSEG, Food and Drug Administration, Bristol Locations: Cambridge, Cambridge , Massachusetts, Eliquis

☆ Jim Cramer identifies an interesting buy level for our worst performing Big Tech stock this year
▼ + stars: | 2024-10-31 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said Thursday that Microsoft shares below $400 each would be an interesting buy level. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m.

Persons: Jim Cramer, Stocks, Thursday's, Eaton, it's, Jim, Linde, Sanjiv Lamba, Estee Lauder, Bristol Myers, Uber, Jim Cramer's Organizations: CNBC, Nasdaq, Microsoft, Apple, Nvidia, Linde, Merck, LIN Locations: SharkNinja

☆ Immunotherapy improves survival in people with advanced Hodgkin lymphoma, study shows
▼ + stars: | 2024-10-16 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +9 min

CNN —An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial. “The standard endpoint in studies of Hodgkin lymphoma is progression-free survival, because we think that best predicts the future,” he said. Hodgkin lymphoma can develop at any age, but it’s most common in early adulthood. ‘An immunotherapy revolution’The new study included nearly 1,000 people who were at least 12 years old and newly diagnosed with stage III or IV Hodgkin lymphoma that had previously been untreated. “However, insights in the field of cancer biology identified other potential approaches to cancer treatment in general and Hodgkin’s lymphoma in particular.

Persons: Hodgkin, Dr, Jonathan Friedberg, ”, ” Friedberg, it’s, Friedberg, Bristol, “, we’ve, Ann LaCasce, Dana, Farber, Brigham, Sanjay Gupta, James Armitage, Dan Longo, ” Armitage, Longo Organizations: CNN, New England, of Medicine, “, Wilmot Cancer Institute, University of Rochester, American Cancer Society, Bristol, Myers Squibb, Food and Drug Administration, FDA, Bristol Myers, Brigham Fellowship, CNN Health, University of Nebraska Medical Center, Brigham, Women’s Locations: United States, Canada, U.S

☆ Bristol Myers Squibb CEO Chris Boerner goes one-on-one with Jim Cramer
▼ + stars: | 2024-09-30 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Bristol Myers Squibb CEO Chris Boerner goes one-on-one with Jim CramerBristol Myers Squibb Chair and CEO Chris Boerner joins 'Mad Money' host Jim Cramer to talk its new Schizophrenia treatment, the company's long-term goals and more.

Persons: Chris Boerner, Jim Cramer Bristol Myers, Jim Cramer Organizations: Bristol Myers, Jim Cramer Bristol Myers Squibb

☆ The one sector of the stock market that is cheap with upside today
▼ + stars: | 2024-09-29 | by ( Karen Firestone | ) www.cnbc.com time to read: +5 min

The table and chart below illustrate some characteristics of the biopharma stocks. The average price/earnings multiple for the group, using 2025 estimates, is 12.7 times versus 20.6 times for the S & P 500. A major knock on the biopharma group is the limited productivity from their extremely expensive research efforts, other than obesity drugs, over the past twenty-five years. The technology using AI might not be ready yet, particularly related to the complex biology of the human body. Complex programs exist already, such as AlphaFold, which predicts the structure of three-dimensional compounds using data on protein sequences.

Persons: Bristol Myers, Amgen, Eli Lilly, Lilly, Johnson Organizations: CNBC, Merck, Pfizer, Novo Nordisk, JPMorgan Locations: Bristol

☆ Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
▼ + stars: | 2024-09-27 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBristol Myers Squibb stock rises following FDA approval of its schizophrenia drugCNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.

Persons: Angelica Peebles Organizations: Bristol Myers Squibb, Bristol Myers

☆ Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more
▼ + stars: | 2024-09-27 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

That came after short-seller Hindenburg Research revealed last month it had taken a short position in the company, citing "fresh evidence of accounting manipulation." Cassava Sciences — The biotech company fell 11% after agreeing to pay $40 million to settle a case with the Securities and Exchange Commission. Wynn Resorts — The stock rose about 6% thanks to an upgrade to overweight from equal weight at Morgan Stanley. Amgen — The biotech's shares rose 2% after Cantor Fitzgerald initiated research coverage with an overweight rating. — The aerospace and defense stock added 16% following a price target increase from KeyBanc Capital Markets, which retained an overweight investment rating.

Persons: Bristol Myers, Hindenburg, Morgan Stanley, Amgen, Cantor Fitzgerald, Olivia Brayer, Michael Leshock, — CNBC's Sean Conlon, Alex Harring, Yun Li, Hakyung Kim, Samantha Subin, Pia Singh Organizations: Bristol Myers Squibb, Food and Drug Administration, Bristol, Nordisk —, JPMorgan, Wall, Costco Wholesale, Revenue, Wall Street Journal, Justice Department, Hindenburg Research, Securities and Exchange Commission, Wynn Resorts, UAE, HP Inc, Bank of America, KeyBanc Locations: Nordisk — U.S, Danish, Las Vegas

☆ 10 things to watch in the stock market Friday including a bullish call on Best Buy
▼ + stars: | 2024-09-27 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

We raised our price target on the stock. Best Buy was added to JPMorgan's analyst focus list after a meeting with the electronics and appliance retailer's management team. Deutsche Bank restarted coverage of Dell Technologies with a buy rating and price target of $144 a share. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Bristol Myers, Morgan Stanley, Wynn, Jim Cramer, Dan Ives, Jim Cramer's, Jim Organizations: Club, Costco, Drug Administration, Bristol, Bristol Myers Squibb, Wynn Resorts, United Arab, Citigroup, Analysts, Walmart, Deutsche Bank, Dell Technologies, PepsiCo, HP Inc, Bank of America, HP, Wedbush Securities, Jim's, Jim Cramer's Charitable, CNBC Locations: what's, New Jersey, Las Vegas, United Arab Emirates, China, Macau

Prices for prescription pharmaceutical drugs have skyrocketed, disproportionately making them harder for people of color to afford, a new report finds. Black people in the U.S. are more likely to be diagnosed with the condition and die from it, the report highlights. Several health care advocacy organizations, including Patients for Affordable Drugs and Health Care for America Now, are pushing for policies that will help lower the financial burden of patients. Both organizations supported the Inflation Reduction Act, a law signed by President Joe Biden that aims to reduce prescription drug prices. In the meantime, Basey, of Patients for Affordable Drugs, said her organization continues to push for bills like S.142, which prevents pharmaceutical companies from paying generic brands to delay the release of their drugs on the market.

Persons: Merith, “, ” Basey, ”, Basey, haven’t, Carrol Olinger, Olinger, ” Olinger, Joe Biden, Margarida Jorge, Jorge, hasn’t, “ It’s, ” Jorge, she’s Organizations: Drugs, New England, of Medicine, AstraZeneca, NBC News, Bristol Myers Squibb, ” Pharmaceutical, U.S, Health Care, America, Centers for Disease Control, Biden Locations: U.S, Daiichi, Hope Mills , North Carolina, Basey

☆ FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades
▼ + stars: | 2024-09-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Food and Drug Administration on Thursday approved Bristol Myers Squibb 's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Bristol Myers Squibb expects the twice-daily pill, which will be sold under the brand name Cobenfy, to be available in late October, executives told CNBC. Cobenfy could also be a huge long-term sales opportunity for Bristol Myers Squibb, which faces pressure to offset the potential loss of revenue from top-selling treatments that will see their patents expire. But they said the drug will likely have a slow launch, so it may not meaningfully contribute to Bristol Myers Squibb's top line in 2024 and 2025. "We've helped people, we've improved outcomes, we've provided caregivers and physicians with another tool that they can use."

Persons: Bristol Myers, Cobenfy, Guggenheim, doesn't, Andrew Miller, We've, we've Organizations: Drug Administration, Bristol, Bristol Myers Squibb, CNBC, Karuna Therapeutics Locations: U.S

☆ Here's where to invest $1 million, according to the pros
▼ + stars: | 2024-09-23 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

If you had as much as a spare $1 million to invest right now, what should you buy? Balanced-to-medium risk profile With as much as $1 million to invest with, investors can buy individual securities instead of being restricted to funds, said David Dietze, managing principal and senior portfolio strategist at Peapack Private Wealth Management. "A much smaller amount leaves an investor forced to invest in funds to get adequate diversification. With one million, one could say invest $20K in fifty different stocks and be well diversified," he said. More aggressive risk profile Gambles says that taking on a more aggressive stance would mean an "all in commitment" on the themes he expects will perform, and removing any hedges against those trades.

Persons: Paul Gambles, David Dietze, Dietze, Bristol Myers, Gambles Organizations: U.S . Federal Reserve, CNBC Pro, Family, Yen, Wealth Management, Bristol, BHP Group, Hershey, BHP Locations: China, Australian

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

The first round of Medicare drug price negotiations has come to an end – but we still don't know the final prices that the U.S. government and pharmaceutical companies have agreed on. They all maintain that Medicare drug price negotiations are a long-term threat to the pharmaceutical industry's drug innovation and profits, but the immediate dust has somewhat settled. That's based on executive commentary during the recent quarterly earnings calls of Bristol Myers Squibb and Johnson & Johnson , among other companies. Novartis CEO Vasant Narasimhan said on July 18 that the short-term impact from Medicare drug price negotiations "might be manageable on our first set of drugs." Executives at each of the drugmakers similarly emphasized their opposition to Medicare drug price negotiations on their respective earnings calls.

Persons: Joe Biden, Johnson, Joe Biden's, Christopher Boerner, Bristol Myers, Robert Michael, We've, Michael, Jennifer Taubert, Vasant Narasimhan, Narasimhan, Bristol Myers Squibb's Boerner, Boehringer Ingelheim, Annika Organizations: National Institutes of Health, Medicare, Bristol Myers Squibb, Johnson, Pfizer, J, Novartis, Merck, Novo Nordisk, AstraZeneca Locations: Bethesda , Maryland, U.S, annikakim.constantino@nbcuni.com

☆ Monday's rapid fire: 3M, Bristol Myers Squibb, McDonald's, On Semiconductor and Colgate-Palmolive
▼ + stars: | 2024-07-29 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMonday's rapid fire: 3M, Bristol Myers Squibb, McDonald's, On Semiconductor and Colgate-PalmoliveCNBC's Jim Cramer on Monday discussed notable stock moves in recent days, including the response to 3M's earnings and McDonald's quarterly results.

Persons: Jim Cramer Organizations: Bristol Myers Squibb, Semiconductor, Colgate, Palmolive Locations: McDonald's

☆ Why Jim Cramer expects 3M to remain a 'big winner' — plus, his thoughts on 4 more stocks
▼ + stars: | 2024-07-29 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. 3M: Shares were slightly lower Monday, giving back some of their 23% surge Friday on the back of a better-than-expected quarter and raised outlook. New CEO Bill Brown, who took over at the industrial firm May 1, had success at L3Harris Technologies and "will be a big winner here," as well, Jim Cramer said. McDonald's : Shares rose 4% despite the fast-food giant reporting weaker-than-expected earnings and revenue along with same-store sales declines. That's the stuff that's moving up" while buzzier chip stocks tied to artificial intelligence, such as Arm Holdings , are struggling, Cramer explained.

Persons: Jim Cramer's, Bill Brown, Jim Cramer, Cramer Organizations: CNBC, Club, L3Harris Technologies, Bristol Myers Squibb, Semiconductor, Wall, Texas Instruments, Arm Holdings, Colgate, Palmolive

☆ Stocks making the biggest moves midday: 3M, Dexcom, Sweetgreen, Texas Roadhouse and more
▼ + stars: | 2024-07-26 | by ( Alex Harring | ) www.cnbc.com time to read: +6 min

Dexcom — Shares plummeted more than 40% after the medical device maker missed expectations for second-quarter revenue and offered weak full-year guidance for the measure. That exceeded analysts' expectations for earnings of $3.48 per share on revenue of $808 million, per LSEG. Norfolk Southern — Shares of the railroad operator gained 10% after a second-quarter earnings beat. Texas Roadhouse — The restaurant chain climbed 4.4% after second-quarter earnings topped expectations. Texas Roadhouse earned $1.79 per share, above the $1.64 per share estimate from analysts surveyed by LSEG.

Persons: Dexcom, Coursera, Newell Brands, Newell, Boston Beer, LSEG, Mohawk, Bristol Myers Squibb, Morgan Stanley, FactSet, amortization, Bitcoin, Alexander, Baldwin —, Alexander & Baldwin, Piper Sandler, Guggenheim, Sweetgreen —, Oppenheimer, Stifel, Yun Li, Pia Singh, Sean Conlon, Jesse Pound, Hakyung Kim, Lisa Kailai Han Organizations: LSEG, Newell, Yankee, Wall, Boston Beer, Boston, Mohawk Industries, Bristol Myers Squibb, Bristol, Revenue, Norfolk Southern, Norfolk, Charter Communications, Southwest Airlines, Deutsche Bank, Southwest, Redburn, FactSet, FTAI Aviation, Texas, Texas Roadhouse, LSEG . Revenue, Colgate, Palmolive Locations: Norfolk

☆ Bristol Myers surges 10%, its biggest increase since 2008, after boosting profit forecast
▼ + stars: | 2024-07-26 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +3 min

Bristol Myers boosted its adjusted earnings for the year to between 60 and 90 cents a share, up 20 cents from its last forecast. AdvertisementOf Bristol Myers' existing drugs, Eliquis saw a 7% increase in sales year-over-year. Cancer drug Opdivo and blood cancer treatment Revlimid also saw promising results and beat quarterly sales estimates. The company reiterated its plan to cut $1.5 billion in costs by 2025, which was announced at its last quarterly earnings call. Bristol Myers is only the latest of a host of other drugmakers to raise their earnings guidance this week.

Persons: Myers, —, Bristol Myers, Christopher Boerner, Eliquis, Revlimid, David Elkins, Boerner, AbbVie Organizations: Bristol, Myers Squibb, Service, Cancer, FDA, AstraZeneca, Roche, Sanofi Locations: Bristol

☆ Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
▼ + stars: | 2024-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Bristol Myers Squibb on Friday reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance as the drugmaker moves to slash costs. The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs. Bristol Myers posted net income of $1.68 billion, or 83 cents per share, for the second quarter. Revenue from Bristol Myers' blood cancer drug Revlimid also topped analysts' estimates for the period despite facing competition from cheaper generics.

Persons: Bristol Myers, Revlimid, Joe Biden's Organizations: Bristol Myers Squibb, LSEG, Revenue Locations: Cambridge, Cambridge , Massachusetts, Bristol, Revlimid

☆ 10 things to watch in the stock market Friday after a tumultuous week
▼ + stars: | 2024-07-26 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

The data didn't sway the market odds on the Fed cutting interest rates three times this year, starting in September. The industrial conglomerate raised its full-year outlook. Two of the Club's industrial names, Honeywell and Dover , reported earnings this week with mixed fortunes for their stocks. Dexcom shares plunged more than 35% after the medical device company missed on revenue and cut its full-year outlook. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Bristol Myers, Abbott, Skechers, Lockheed Martin, L3Harris, Japan's Eisai, Eli Lilly, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Federal, Transportation, Electronics, Honeywell, Colgate, Palmolive, Abbott Laboratories, Libre, Deutsche Bank, Lockheed, EU, Novo Nordisk, Jim Cramer's Charitable, CNBC Locations: Dover

☆ Stocks making the biggest moves premarket: Coursera, WW International, DexCom, Deckers and more
▼ + stars: | 2024-07-26 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Dexcom — The medical device stock plummeted more than 36% after the company posted a second-quarter revenue miss. The company's $579 million revenue was also lower than the consensus estimate of $597 million. Coursera — The online course provider stock surged 26% after Coursera posted second-quarter revenue of $170 million, which exceeded the $164 million analysts had expected, according to LSEG. 3M — The industrials giant added nearly 7% after posting second-quarter adjusted earnings of $1.93 and adjusted revenue of $6.02 billion. Charter's $13.69 billion revenue also exceeded the $13.59 billion analysts had expected.

Persons: George Kurtz, LSEG, Dexcom, Boston Beer, Coursera, Bristol Myers, Morgan Stanley, —, Alex Harring, Sarah Min, Jesse Pound Organizations: Semiconductor, Nvidia, Broadcom, Devices, Qualcomm, Micron Technology, Boston Beer, Boston, Mohawk Industries, Mohawk, Bristol Myers Squibb, Bristol, Revenue, Norfolk Southern, Charter Communications

☆ Stocks on the move: Bristol Myers, Abbive, and Tesla
▼ + stars: | 2024-07-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStocks on the move: Bristol Myers, Abbive, and TeslaThe Investment Committee discuss some of their stocks that are on the move today

Persons: Bristol Myers, Abbive

Search resuls for: "Bristol Myers"

25 mentions found